Aceptar todas las «cookies» garantizará que puedas disfrutar de la mejor experiencia en nuestro sitio web, incluyendo la personalización del contenido y las funciones para redes sociales. Aceptar únicamente las «cookies» necesarias permitirá un uso mínimo de «cookies» mientras navegas, pero es posible que algunas partes del sitio web no se muestren correctamente. Para saber más, consulta nuestra política de privacidad.
15th EGA Regulatory and Scientific Affairs Conference had offered an update on recent regulatory developments, and answered the following answers:
- Looking to the future- EMA/HMA Strategy 2020 Work Plan- how will it impact the regulatory environment for pharmaceuticals?
- Tackling effects of the globalisation of pharmaceutical operations – challenges, opportunities and priorities
- Maintenance of medicinal products: is there a better way of handling it in practice?
- Borderline medicinal products - Do on-going changes to medical devices, food supplement legislations impact my products?
- How does the ICH 3QD guideline on elemental impurities affect my products?
- ISO IDMP is around the corner: are we set and ready to start with implementation?
Key Takeaways
- Regulatory implications of various changes in the legal and operational environment
- Electronic submission environment
Photos
Romuald Braun and Bernard Ferber at Amplexor's booth